Bone drug breakthrough: could less be more for cancer patients?

NCT ID NCT04549207

First seen Dec 10, 2025 · Last updated May 09, 2026 · Updated 19 times

Summary

This study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this approach maintains quality of life and prevents bone complications. About 240 adults will be randomly assigned to either continue or de-escalate their treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • Southlake Regional Health Centre

    Newmarket, Ontario, L3Y 2P9, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Thunder Bay Regional Health Sciences Centre

    Thunder Bay, Ontario, P7B 6V4, Canada

  • William Osler Health System

    Brampton, Ontario, L6R 3J7, Canada

Conditions

Explore the condition pages connected to this study.